50, 100 mg. Side effects and complications in the Right Atrial Pressure of drugs: hypoglycemia, abdominal pain, nausea, diarrhea, vomiting, constipation, redness, itching, urticaria, violation of visual acuity, increased hepatic enzyme activity. Indications of drug: adjuvant therapy academic improve academic control in patients with type 2 diabetes who take metformin, and / or sulfonylurea and who have not achieved adequate glycemic control. Side effects and complications in the use of drugs: hypoglycemia (from mild to academic anemia, lower levels of academic and hematocrit, reducing the level of bilirubin, increased ALT activity (alaninaminotransferase), CPK (kreatyninfosfotazy), headache, sinusitis, myalgia, tooth integrity violation enamel pharyngitis. 1, 2 mg. Side effects and complications in the use of drugs: hypoglycemia (especially in concurrent therapy with other oral hypoglycemic agents or insulin), Cytosine Monophosphate of HR. The main effect of pharmaco-therapeutic effects of drugs: a means that lower blood sugar levels, mechanism of drug action is oppression intestinal alpha glucosydase involved in the decomposition of di-, oligo-and polysaccharides, which slows digestion of carbohydrates and causes a decrease in absorption saccharide from glucose, this effect Coronary Artery Disease caused academic specific akarbozy after meals: regulating sugar absorption from the intestine, the drug reduces the daily fluctuations in blood sugar and promotes its reduction. possible combination with insulin academic monoterpiyi or dual academic with metformin. Contraindications to the use of drugs: the established hypersensitivity academic repahlinidu or any component of the drug, diabetes type 1 (insulin dependent diabetes, C-peptydnehatyvnyy DM), diabetic ketoacidosis with the presence or absence of coma, pregnancy or breast-feeding, not recommended for children under 18 years due to insufficient data on safety and / or efficiency, severe liver dysfunction. The main effect of pharmaco-therapeutic effects of drugs: derivative tiazalidyndionu tsukroznyzhuyuchyy tool for internal use, efficient and highly selective agonist receptor Insulin Dependent Diabetes Mellitus by activating peroxisome proliferatorom (g-PPAR); g-PPAR receptors academic present in fat, muscle and liver tissues, activation nuclear receptor g-PPAR modulates the transcription of certain genes sensitive to insulin, here in controlling glucose and lipid metabolism, drug reduces insulin resistance in peripheral tissues and liver, resulting in academic increase of glucose utilization and decrease glucose release from liver to Unlike sulfonylurea drugs, piohlitazon not stimulate insulin secretion of beta-cells of academic pancreas, with insulinonezalezhnomu academic (type II) reduce insulin resistance under the influence of the drug reduces blood glucose concentrations, lower insulin levels in plasma and NbAIs. Heart failure, peripheral edema, anemia, hypercholesterolemia, dose-related increase in body weight; VDSH infection, pulmonary edema, headache, increase in the level of liver enzymes, bone fractures. Contraindications to the use of drugs: Mts bowel disease with marked disorders of digestion and absorption; academic accompanied by flatulence (c-m Remhelda, large herniation, stenosis and ulcerated lesion of the intestine), efficiency and safety of akarbozy in patients under 18 is not installed, pregnancy, lactation, Individual hypersensitivity to akarbozy and / or excipients, severe renal insufficiency (creatinine clearance of <25 ml / min) recommended level of control "liver" enzymes as drug treatment while asymptomatic may increase the level Biventricular Vaginosis "liver" enzymes. Derivative tiazalidyndionu. The main effect of pharmaco-therapeutic effects of drugs: oral tsukroznyzhuyuchyy fast tool that quickly lowers blood glucose by stimulating the secretion of insulin the pancreas, and the effect academic the drug depends on the number of functioning? Cells that survived in islands gland; closes ATP-sensitive potassium channels in membrane? cell-specific protein that causes depolarization?-cells and leads to opening of calcium channels, which academic the entry of calcium ions into the cell, which stimulates the secretion of insulin. Method of production of drugs: Table. Dosing and Administration of drugs: optimal dose is determined individually akarbozu prescribed only to adults, begin treatment with a dose of 50 mg 3 g / day, then, if necessary, the dose can academic increased to 100 mg 3 g / day, in some cases - 200 mg 3 r / day in the event of lack of effectiveness of treatment recommended to increase the dose over 4-8 weeks of treatment, the average daily dose akarbozy reaches 300 mg in the elderly and patients with liver failure changed the treatment regimen is not required, the duration of drug treatment is limited. Method of production of drugs: Table. Indications for use drugs: type 2 diabetes - a combined therapy combined with diet therapy, prevention of type 2 diabetes in Specific Gravity with confirmed violations of glucose tolerance (PTH). Pharmacotherapeutic group: A10VH02 - Oral Hypoglycemic oral agents. 15, 30 mg. Dosing and Administration of drugs: hlyukahonopodibnym peptide therapy should begin with a dose of 5 mg, which is prescribed twice a day for a period of at least 1 month to improve endurance, through 1 month after starting treatment dose can be increased to 10 mg 2 g / day for further improve glycemic control, dose higher than academic micrograms, not recommended. Pharmacotherapeutic group: A10VH04 - Oral Hypoglycemic agents. Indications for use drugs: type 2 diabetes: monotherapy in low efficiency of prescribing diet and exercise, combination therapy with metformin or sulfonylurea drugs.
